Chloroquine-resistant falciparum malaria from East Africa.
Seven patients (one black African and six white Europeans) developed chloroquine-resistant falciparum malaria in East Africa. In vitro studies confirmed chloroquine resistance in three patients, but the parasites failed to grow in the other four patients. Six patients were cured by sequential quinine and Fansidar, one by sequential quinine and mefloquine.
D000328:Adult; D000351:Africa, Eastern; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology / Q000517:prevention & control; D008297:Male; D015767:Mefloquine; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000187:drug effects*; D011739:Pyrimethamine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use
D004338:Drug Combinations; D011804:Quinolines; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011803:Quinine; D015767:Mefloquine; D011739:Pyrimethamine